Dramatic growth in the use of generic drugs has generated substantial savings for American consumers. To examine how the Department of Health and Human Services (HHS) can encourage the use of generic drugs, the Assistant Secretary for Planning and Evaluation (ASPE) examined barriers to, and opportunities for, expanding the use of generic drugs.
Prescription Drugs & Other Medical Products
Drugs and other medical products greatly impact human health and the health care system. ASPE conducts a variety of research in this area, including work related to medical product development and regulation; medical product markets, pricing and competition; prescription drug benefits and spending on medical products; medical product supply chains; and medical product safety.
Noteworthy
Reports
Displaying 131 - 140 of 178. 10 per page. Page 14.
Advanced SearchMedicaid Contracts with Medicare Special Needs Plans Reflect Diverse State Approaches to Dually Eligible Beneficiaries
U.S. Department of Health and Human Services
State Purchasing Strategies Drive State Contracts with Medicare Special Needs Plans
U.S. Department of Health and Human Services
Payment for Medicare Advantage Plans: Policy Issues and Options
Medicare Advantage (MA) is the current program under which beneficiaries can enroll in private health plans rather than having their care covered through Medicare's traditional fee for service (FFS) program. Payments to MA plans in many areas are now substantially greater than the cost of treating comparable beneficiaries in the traditional program.
Federal Authority for Medicare Special Needs Plans and their Relationship to State Medicaid Programs
This Brief reviews the history and current status of federal special needs plans (SNPs) authority, with particular attention to provisions of interest to state Medicaid programs that have or are considering entering into contracts with SNPs to integrate or coordinate Medicaid long-term care services with Medicare primary, acute and prescription drug services for dually eligible beneficiaries.
A Framework for Evaluating Quality Transparency Initiatives in Health Care
To date a number of private and public sector initiatives have commenced that rely on value-driven principles for the delivery of health care services. Given the variation that may exist across these initiatives it is important to have a good structure for examining and evaluating their implementation and overall effectiveness.
A Framework for Evaluating Price Transparency Initiatives in Health Care
To date a number of private and public sector initiatives have commenced that rely on value-driven principles for the delivery of health care services. Given the variation that may exist across these initiatives it is important to have a good structure for examining and evaluating their implementation and overall effectiveness.
Prescription Drug Spending by Medicare Beneficiaries in Institutional and Residential Settings, 1998-2001
U.S. Department of Health and Human Services
A National Comparison of Prescription Drug Expenditures by Medicare Beneficiaries Living in the Community and Long-Term Care Facility Settings
This Policy Brief provides a snapshot of prescription drug use and spending in 2001, the latest year for which complete community and long-term care facility drug data are available.
Drug Use and Spending for Medicare Beneficiaries During Part A Qualifying Skilled Nursing Facility Stays and Non-Qualifying Long-Term Care Facility Stays
This Policy Brief helps fill an important gap in our understanding of medication patterns in long-term care facilities (LTCFs) by comparing use and spending for prescription and over-the-counter drugs during skilled nursing facility (SNF) stays and related non-qualifying long-term care facility episodes.